Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.

Literature DB >> 26854424

Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.

Danielle M Gerhard¹, Eric S Wohleb², Ronald S Duman³.

Abstract

Major depression is a chronic and debilitating illness that effects approximately 1 in 5 people, but currently available treatments are limited by low rates of efficacy, therapeutic time lag, and undesirable side effects. Recent efforts have been directed towards investigating rapid-acting agents that reverse the behavioral and neuronal deficits of chronic stress and depression, notably the glutamate NMDA receptor antagonist ketamine. The cellular mechanisms underlying the rapid antidepressant actions of ketamine and related agents are discussed, as well as novel, selective glutamatergic receptor targets that are safer and have fewer side effects.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2016 PMID： 26854424 PMCID： PMC4803609 DOI： 10.1016/j.drudis.2016.01.016

Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851

100 in total

1. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112

2. Scopolamine produces larger antidepressant and antianxiety effects in women than in men.

Authors: Maura L Furey; Ashish Khanna; Elana M Hoffman; Wayne C Drevets
Journal: Neuropsychopharmacology Date: 2010-08-25 Impact factor: 7.853

3. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors: B Moghaddam; B Adams; A Verma; D Daly
Journal: J Neurosci Date: 1997-04-15 Impact factor: 6.167

4. BDNF Val66Met polymorphism is associated with higher anticipatory cortisol stress response, anxiety, and alcohol consumption in healthy adults.

Authors: Lorenza S Colzato; A J Willem Van der Does; Coen Kouwenhoven; Bernet M Elzinga; Bernhard Hommel
Journal: Psychoneuroendocrinology Date: 2011-05-18 Impact factor: 4.905

5. Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: a laminar analysis using the silver-enhanced diaminobenzidine sulfide (SEDS) immunolabeling technique.

Authors: J F Smiley; P S Goldman-Rakic
Journal: Cereb Cortex Date: 1993 May-Jun Impact factor: 5.357

Review 6. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide.

Authors: Jonathan Savitz; Wayne C Drevets
Journal: Neurosci Biobehav Rev Date: 2009-01-21 Impact factor: 8.989

7. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors: Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal: Biol Psychiatry Date: 2010-01-15 Impact factor: 13.382

8. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

Authors: Jeffrey Burgdorf; Xiao-lei Zhang; Katherine L Nicholson; Robert L Balster; J David Leander; Patric K Stanton; Amanda L Gross; Roger A Kroes; Joseph R Moskal
Journal: Neuropsychopharmacology Date: 2012-12-05 Impact factor: 7.853

9. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors: Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal: Nature Date: 2011-06-15 Impact factor: 49.962

10. BDNF release is required for the behavioral actions of ketamine.

Authors: Ashley E Lepack; Manabu Fuchikami; Jason M Dwyer; Mounira Banasr; Ronald S Duman
Journal: Int J Neuropsychopharmacol Date: 2014-10-31 Impact factor: 5.176

80 in total

Review 1. Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.

Authors: Gislaine Zilli Réus; Airam Barbosa de Moura; Laura Araújo Borba; Helena Mendes Abelaira; João Quevedo
Journal: Mol Neuropsychiatry Date: 2019-05-21

Review 2. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors: Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal: Drugs Date: 2017-03 Impact factor: 9.546

3. Ketamine induces immediate and delayed alterations of OCD-like behavior.

Authors: Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa
Journal: Psychopharmacology (Berl) Date: 2020-01-11 Impact factor: 4.530

Review 4. Druggable Transcriptional Networks in the Human Neurogenic Epigenome.

Authors: Gerald A Higgins; Aaron M Williams; Alex S Ade; Hasan B Alam; Brian D Athey
Journal: Pharmacol Rev Date: 2019-10 Impact factor: 25.468

Review 5. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors: Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal: Pharmacol Rev Date: 2018-07 Impact factor: 25.468

6. Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders.

Authors: Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos
Journal: Antioxid Redox Signal Date: 2019-02-01 Impact factor: 8.401

7. GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions.

Authors: Danielle M Gerhard; Santosh Pothula; Rong-Jian Liu; Min Wu; Xiao-Yuan Li; Matthew J Girgenti; Seth R Taylor; Catharine H Duman; Eric Delpire; Marina Picciotto; Eric S Wohleb; Ronald S Duman
Journal: J Clin Invest Date: 2020-03-02 Impact factor: 14.808